Shanghai SynTheAll Pharmaceuticals Co., Ltd. (STA) Receives ISO 14001 Certification
SHANGHAI, Sept. 3 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that its manufacturing subsidiary, Shanghai SynTheAll Pharmaceuticals Co. Ltd. (STA) passed the ISO 14001: 2004 inspection conducted by SGS Group on July 1 and received formal ISO 14001 certification on July 30.
SGS Group is an inspection, verification, testing, and certification company. The International Organization for Standardization (ISO) is the world's largest developer and publisher of International Standards. ISO 14001 certification relates specifically to environmental management. Receiving ISO 14001 certification issued by SGS Group is a testimony to the well-organized, well-conducted, and well-documented environmental practice at STA in areas such as wastewater management, air emissions, and organic waste disposal.
"As a result of an extensive on-site evaluation, SGS Group certified that this facility meets the highest international standards of environmental practice and on-site management," said Dr. Weimin Chang, Vice President of Operations and General Manager of STA. "As STA is now certified by SGS Group for ISO 9001 for quality management as well as for ISO 14001 for environmental management, we are confident that STA will pass environmental health and safety audits from our customers and government agencies. The staff at STA considers environment protection to be a social responsibility. We spare no effort to save energy, cut emissions, and implement practices for sustainable development while providing our customers with the highest quality of service."
For more information, please contact: Ronald Aldridge (for investors) Tel: +1-201-585-2048 Email: Ron_Aldridge@wuxiapptec.com Stephanie Liu (for the media) Tel: +86-21-5046-4362 Email: email@example.com
SOURCE WuXi PharmaTech
More by this Source
WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2013 Results
Mar 05, 2014, 16:30 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.